{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:36:38Z","timestamp":1783676198372,"version":"3.55.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015631","name":"Gallaudet University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ucl.2024.03.014","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T16:35:15Z","timestamp":1713285315000},"page":"355-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune-based Therapies for Penile Cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"Majd","family":"Al Assaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssein","family":"Safa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2024.03.014_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221127254","article-title":"An update on treatment of penile cancer","volume":"14","author":"Chadha","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib3","first-page":"960","article-title":"Patterns of recurrence following inguinal lymph node dissection for penile cancer: optimizing surveillance strategies","volume":"206","author":"Chakiryan","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.014_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1590\/s1677-5538.ibju.2020.0959","article-title":"Prognostic predictors of lymph node metastasis in penile cancer: a systematic review","volume":"47","author":"Zekan","year":"2021","journal-title":"Int Braz J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"21","key":"10.1016\/j.ucl.2024.03.014_bib6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.21037\/atm-20-1802","article-title":"Incidence trends and survival outcomes of penile squamous cell carcinoma: evidence from the Surveillance, Epidemiology and End Results population-based data","volume":"8","author":"Qi","year":"2020","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ijc.21009","article-title":"Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease","volume":"116","author":"Daling","year":"2005","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","article-title":"Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis","volume":"20","author":"Olesen","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.014_bib9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.21037\/tau.2017.07.24","article-title":"Psychosocial impact of penile carcinoma","volume":"6","author":"Audenet","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib10","doi-asserted-by":"crossref","first-page":"151286","DOI":"10.1016\/j.soncn.2022.151286","article-title":"Importance of Addressing the Psychosocial Impact of Penile Cancer on Patients and Their Families","volume":"38","author":"Paster","year":"2022","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ucl.2024.03.014_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2490-9-8","article-title":"Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer","volume":"9","author":"Maddineni","year":"2009","journal-title":"BMC Urol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10552-021-01493-3","article-title":"Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma","volume":"33","author":"Wenzel","year":"2022","journal-title":"Cancer Causes Control"},{"issue":"24","key":"10.1016\/j.ucl.2024.03.014_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246024","article-title":"Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up","volume":"14","author":"Chahoud","year":"2022","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.ucl.2024.03.014_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143713","article-title":"The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma-A Systematic Review","volume":"15","author":"Parza","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib15","doi-asserted-by":"crossref","first-page":"e2348002","DOI":"10.1001\/jamanetworkopen.2023.48002","article-title":"Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden","volume":"6","author":"Necchi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ucl.2024.03.014_bib16","doi-asserted-by":"crossref","first-page":"102087","DOI":"10.1016\/j.ctrv.2020.102087","article-title":"Current management and future perspectives of penile cancer: An updated review","volume":"90","author":"Peyraud","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.mayocp.2020.06.031","article-title":"Management of Advanced Penile Cancer","volume":"96","author":"Chahoud","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1590\/abd1806-4841.20175009","article-title":"Penile squamous cell carcinoma: a review of the literature and case report treated with Mohs micrographic surgery","volume":"92","author":"Marchionne","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.ucl.2024.03.014_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.urolonc.2020.08.001","article-title":"Second line salvage systemic therapy for advanced penile cancer","volume":"40","author":"Chahoud","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncpuro0751","article-title":"Prognostic factors in squamous cell carcinoma of the penis","volume":"4","author":"Novara","year":"2007","journal-title":"Nat Clin Pract Urol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2008.04.016","article-title":"Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients","volume":"54","author":"Leijte","year":"2008","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MOU.0000000000000714","article-title":"Management of the penile squamous cell carcinoma patient after node positive radical inguinal lymph node dissection: current evidence and future prospects","volume":"30","author":"de Vries","year":"2020","journal-title":"Curr Opin Urol"},{"issue":"24","key":"10.1016\/j.ucl.2024.03.014_bib23","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ucl.2010.04.010","article-title":"Chemotherapy for penile and urethral carcinoma","volume":"37","author":"Trabulsi","year":"2010","journal-title":"Urol Clin North Am"},{"issue":"8","key":"10.1016\/j.ucl.2024.03.014_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41585-022-00617-x","article-title":"Immune-based therapies in penile cancer","volume":"19","author":"Joshi","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2024.03.014_bib26","doi-asserted-by":"crossref","first-page":"615298","DOI":"10.3389\/fonc.2020.615298","article-title":"Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab","volume":"10","author":"Chahoud","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors","volume":"115","author":"El Zarif","year":"2023","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.014_bib28","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10637-021-01100-x","article-title":"Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial","volume":"39","author":"Hahn","year":"2021","journal-title":"Invest N Drugs"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2024.03.014_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2023.41.6_suppl.8","article-title":"Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic squamous cell penile carcinoma: Initial results of PULSE study","volume":"41","author":"Thiery-Vuillemin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2024.03.014_bib30","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2023.41.16_suppl.5043","article-title":"Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis","volume":"41","author":"Garcia del Muro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib31","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2024.03.014_bib32","doi-asserted-by":"crossref","first-page":"TPS5094","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5094","article-title":"A\u00a0phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial)","volume":"40","author":"Renninson","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2024.03.014_bib33","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1200\/JCO.2022.40.16_suppl.5037","article-title":"Anti-EGFR antibody plus anti-PD-1 antibody and chemotherapy as a neoadjuvant regimen for patients with locally-advanced penile squamous cell carcinoma: A prospective, single-arm, single-center, phase II clinical trial","volume":"40","author":"An","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bju.15828","article-title":"First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer","volume":"131","author":"Yan","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib35","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41467-020-15980-9","article-title":"Effective combinatorial immunotherapy for penile squamous cell carcinoma","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"issue":"31","key":"10.1016\/j.ucl.2024.03.014_bib36","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2024.03.014_bib37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"issue":"31","key":"10.1016\/j.ucl.2024.03.014_bib38","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1200\/JCO.22.02894","article-title":"Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial","volume":"41","author":"de Vries","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2024.03.014_bib39","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2023.41.16_suppl.2597","article-title":"Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and\/or metastatic squamous cell carcinoma (SCC)","volume":"41","author":"Le Tourneau","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOU.0000000000000941","article-title":"Innovative systemic therapies for penile cancer","volume":"32","author":"Chahoud","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.014_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.21037\/tau.2017.06.27","article-title":"Relationship between human papillomavirus and penile cancer-implications for prevention and treatment","volume":"6","author":"Kidd","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ucl.2024.03.014_bib42","doi-asserted-by":"crossref","first-page":"107481","DOI":"10.1016\/j.intimp.2021.107481","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients","volume":"94","author":"Aydin","year":"2021","journal-title":"Int Immunopharm"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2024.03.014_bib43","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.ucl.2024.03.014_bib45","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I\/II Study","volume":"37","author":"Doran","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.ucl.2024.03.014_bib47","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib49","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ajcp\/aqad107","article-title":"Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters: A study of 134 patients","volume":"161","author":"Lobo","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"3 Pt 1","key":"10.1016\/j.ucl.2024.03.014_bib51","first-page":"690","article-title":"Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status","volume":"197","author":"Ottenhof","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2024.03.014_bib52","doi-asserted-by":"crossref","first-page":"874213","DOI":"10.3389\/fmed.2022.874213","article-title":"Immunotherapy in penile squamous cell carcinoma: present or future? multi-target analysis of programmed cell death ligand 1 expression and microsatellite instability","volume":"9","author":"Montella","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib53","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.euo.2018.07.010","article-title":"PD-L1 expression in men with penile cancer and its association with clinical outcomes","volume":"2","author":"Davidsson","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib54","doi-asserted-by":"crossref","first-page":"e1269047","DOI":"10.1080\/2162402X.2016.1269047","article-title":"Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma","volume":"6","author":"Deng","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ucl.2024.03.014_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","article-title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma","volume":"142","author":"Tekin","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ucl.2024.03.014_bib56","doi-asserted-by":"crossref","first-page":"1013806","DOI":"10.3389\/fonc.2022.1013806","article-title":"PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2024.03.014_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071796","article-title":"Immunophenotypes based on the tumor immune microenvironment allow for unsupervised penile cancer patient stratification","volume":"12","author":"Chu","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib58","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.clgc.2019.10.014","article-title":"PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region","volume":"18","author":"De Bacco","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2024.03.014_bib59","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2024.03.014_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","article-title":"Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort","volume":"59","author":"Cocks","year":"2017","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.ucl.2024.03.014_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11101927","article-title":"Factors influencing concordance of pd-l1 expression between biopsies and cytological specimens in non-small cell lung cancer","volume":"11","author":"Mansour","year":"2021","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.4103\/ijc.IJC_920_19","article-title":"Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry","volume":"59","author":"Mishra","year":"2022","journal-title":"Indian J Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2024.03.014_bib63","first-page":"100532","article-title":"Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.30699\/ijp.2023.1988955.3057","article-title":"Evaluation of programmed death - ligand 1 (Pd-L1) expression in head and neck squamous cell carcinoma","volume":"18","author":"Unnikrishnan","year":"2023","journal-title":"Iran J Pathol"},{"key":"10.1016\/j.ucl.2024.03.014_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CMAR.S152232","article-title":"The relationship between the PD-1\/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance","volume":"10","author":"Feng","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/br.2023.1627","article-title":"Programmed death-ligand 1 expression in tumor cells and tumor-infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer","volume":"19","author":"Sangkhamanon","year":"2023","journal-title":"Biomed Rep"},{"key":"10.1016\/j.ucl.2024.03.014_bib67","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.014_bib68","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euf.2019.02.019","article-title":"Defining the tumor microenvironment of penile cancer by means of the cancer immunogram","volume":"5","author":"de Vries","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib70","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s13277-014-2864-2","article-title":"Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence","volume":"36","author":"Vassallo","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0897.2008.00590.x","article-title":"Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma","volume":"60","author":"Adurthi","year":"2008","journal-title":"Am J Reprod Immunol"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib72","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2024.03.014_bib73","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ucl.2024.03.014_bib74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A\u00a0prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J\u00a0Transl Med"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib75","doi-asserted-by":"crossref","first-page":"e1049804","DOI":"10.1080\/2162402X.2015.1049804","article-title":"Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)","volume":"4","author":"Becht","year":"2015","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.ucl.2024.03.014_bib76","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3109\/00016489.2016.1164341","article-title":"The ratio of CD4\/CD8 T-cells in human papillomavirus-positive laryngeal squamous cell carcinoma accounts for improved outcome","volume":"136","author":"Zhang","year":"2016","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib77","doi-asserted-by":"crossref","first-page":"e965570","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlov\u00e1","year":"2015","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00262-016-1805-x","article-title":"A\u00a0beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency","volume":"65","author":"Punt","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ucl.2024.03.014_bib79","first-page":"104335","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in penile cancer: A systematic review and meta-analysis","volume":"81","author":"Saputra","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.ucl.2024.03.014_bib80","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12885-016-2443-6","article-title":"Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer","volume":"16","author":"Kasuga","year":"2016","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.ucl.2024.03.014_bib81","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2217\/fon-2016-0283","article-title":"Are virus-induced cancers more sensitive to checkpoint inhibitors?","volume":"12","author":"Kanaan","year":"2016","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib82","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/ijc.28411","article-title":"The interplay between HPV and host immunity in head and neck squamous cell carcinoma","volume":"134","author":"Andersen","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ucl.2024.03.014_bib83","doi-asserted-by":"crossref","first-page":"682030","DOI":"10.3389\/fimmu.2021.682030","article-title":"Distinct patterns of myeloid cell infiltration in patients with hrHPV-Positive and hrHPV-negative penile squamous cell carcinoma: the importance of assessing myeloid cell densities within the spatial context of the tumor","volume":"12","author":"Rafael","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib84","doi-asserted-by":"crossref","first-page":"Fso88","DOI":"10.4155\/fso.15.88","article-title":"Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma","volume":"2","author":"Matlung","year":"2016","journal-title":"Future Sci OA"},{"issue":"11","key":"10.1016\/j.ucl.2024.03.014_bib85","doi-asserted-by":"crossref","first-page":"e1356148","DOI":"10.1080\/2162402X.2017.1356148","article-title":"The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis","volume":"6","author":"de Ruiter","year":"2017","journal-title":"OncoImmunology"},{"issue":"27","key":"10.1016\/j.ucl.2024.03.014_bib86","doi-asserted-by":"crossref","first-page":"44418","DOI":"10.18632\/oncotarget.17901","article-title":"Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma","volume":"8","author":"Lechner","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ucl.2024.03.014_bib87","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-17-0299","article-title":"Prognostic significance of PD-L1(+) and CD8(+) immune cells in HPV(+) oropharyngeal squamous cell carcinoma","volume":"6","author":"Solomon","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ucl.2022.09.013","article-title":"The evolving landscape of viral, immune, and molecular biomarkers in penile cancer","volume":"50","author":"Yu","year":"2023","journal-title":"Urol Clin North Am"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib90","article-title":"Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa","volume":"10","author":"Tsai","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib91","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib92","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.014_bib93","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"25","key":"10.1016\/j.ucl.2024.03.014_bib94","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6230","key":"10.1016\/j.ucl.2024.03.014_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ucl.2024.03.014_bib96","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6230","key":"10.1016\/j.ucl.2024.03.014_bib97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib98","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.ucl.2024.03.014_bib99","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.014_bib100","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/oncolo\/oyac144","article-title":"Advanced squamous cell carcinomas of the pelvic and perineal region: a comprehensive genomic profiling study","volume":"27","author":"Necchi","year":"2022","journal-title":"Oncol"},{"issue":"24","key":"10.1016\/j.ucl.2024.03.014_bib101","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.34982","article-title":"Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers","volume":"129","author":"Nazha","year":"2023","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.ucl.2024.03.014_bib102","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6349","key":"10.1016\/j.ucl.2024.03.014_bib103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.014_bib104","first-page":"541","article-title":"Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy","volume":"201","author":"Jacob","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"11","key":"10.1016\/j.ucl.2024.03.014_bib105","doi-asserted-by":"crossref","first-page":"12438","DOI":"10.1002\/cam4.5953","article-title":"TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors","volume":"12","author":"Kim","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ucl.2024.03.014_bib106","doi-asserted-by":"crossref","first-page":"102990","DOI":"10.1016\/j.ebiom.2020.102990","article-title":"Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"60","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib107","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOU.0000000000000640","article-title":"Genetics and penile cancer: recent developments and implications","volume":"29","author":"Chahoud","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.014_bib108","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2018","journal-title":"Oncotarget"},{"issue":"29","key":"10.1016\/j.ucl.2024.03.014_bib109","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2024.03.014_bib110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.oraloncology.2017.09.002","article-title":"Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma","volume":"74","author":"Faden","year":"2017","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.014_bib111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014324000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014324000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:53:03Z","timestamp":1719283983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014324000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0094014324000399"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2024.03.014","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-based Therapies for Penile Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2024.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}